Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson’s disease

[1]  A. Björklund,et al.  Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain , 2016, Proceedings of the National Academy of Sciences.

[2]  A. Björklund,et al.  Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson’s disease , 2015, Acta Neuropathologica Communications.

[3]  R. Barker,et al.  G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s disease , 2015, npj Parkinson's Disease.

[4]  C. Olanow,et al.  Levodopa: Effect on cell death and the natural history of Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[5]  S. Dunnett,et al.  Dopamine-rich grafts alleviate deficits in contralateral response space induced by extensive dopamine depletion in rats , 2013, Experimental Neurology.

[6]  S. Dunnett,et al.  Comparison of rating scales used to evaluate l-DOPA-induced dyskinesia in the 6-OHDA lesioned rat , 2013, Neurobiology of Disease.

[7]  K. Elisabet Ohlin,et al.  Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease , 2012, NeuroImage.

[8]  G. Nikkhah,et al.  Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation , 2011, Experimental Neurology.

[9]  S. Dunnett,et al.  Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates , 2011, Journal of Neuroscience Methods.

[10]  P. Brundin,et al.  Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats , 2009, Experimental Neurology.

[11]  M. Cenci,et al.  Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease , 2009, Neuropsychopharmacology.

[12]  K. Steece-Collier,et al.  Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats , 2009, The Journal of comparative neurology.

[13]  G. Meredith,et al.  The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors , 2008, Neurobiology of Disease.

[14]  R. Farinotti,et al.  Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood–brain barrier in a rat brain endothelial cell model , 2008, Neuroscience Letters.

[15]  S. Dunnett,et al.  Improved survival of young donor age dopamine grafts in a rat model of Parkinson’s disease , 2007, Neuroscience.

[16]  A. Sanchez‐Mazas.  An apportionment of human HLA diversity. , 2007, Tissue antigens.

[17]  A. Fietta,et al.  Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. , 2007, Blood.

[18]  S. Dunnett,et al.  An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections , 2006, Journal of Neuroscience Methods.

[19]  J. Nyengaard,et al.  Endothelial Proliferation and Increased Blood–Brain Barrier Permeability in the Basal Ganglia in a Rat Model of 3,4-Dihydroxyphenyl-l-Alanine-Induced Dyskinesia , 2006, The Journal of Neuroscience.

[20]  M. Cenci,et al.  The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat , 2006, Neurobiology of Disease.

[21]  A. Björklund,et al.  Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia , 2006, Neurobiology of Disease.

[22]  N. Kahveci,et al.  Effects of intranigral vs intrastriatal fetal mesencephalic neural grafts on motor behavior disorders in a rat Parkinson model. , 2005, Surgical neurology.

[23]  A. Dagher,et al.  Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. , 2005, Brain : a journal of neurology.

[24]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[25]  I. Mendez,et al.  Functional Improvement with Low-dose Dopaminergic Grafts in Hemiparkinsonian Rats , 2004, Neurosurgery.

[26]  C. Olanow.  Present and future directions in the management of motor complications in patients with advanced PD , 2003, Neurology.

[27]  R. Moots,et al.  Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study , 2002, Journal of Neuroimmunology.

[28]  A. Björklund,et al.  Dyskinesias following neural transplantation in Parkinson's disease , 2002, Nature Neuroscience.

[29]  P. Brundin,et al.  Cell Survival and Clinical Outcome Following Intrastriatal Transplantation in Parkinson Disease , 2001, Journal of neuropathology and experimental neurology.

[30]  A. Björklund,et al.  Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. , 2000, Brain : a journal of neurology.

[31]  S. Tayebati,et al.  Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. , 1999, Journal of autonomic pharmacology.

[32]  S. Tayebati,et al.  Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes , 1999, Journal of Neuroimmunology.

[33]  C. Olanow,et al.  Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. , 1999, Archives of neurology.

[34]  F. Amenta,et al.  Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [ 3 H ]7-OH-DPAT: a combined radioligand binding assay and immunochemical study , 1998, Journal of Neuroimmunology.

[35]  J. Hedreen.  What was wrong with the Abercrombie and empirical cell counting methods? A review , 1998, The Anatomical record.

[36]  A. Rajput,et al.  Is levodopa toxic to human substantia nigra? , 1997, Movement disorders : official journal of the Movement Disorder Society.

[37]  S. DeKosky,et al.  Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. , 1997, Cell transplantation.

[38]  R. Michler,et al.  The influence of concordant xenografts on the humoral and cell-mediated immune responses to subsequent allografts in primates. , 1996, The Journal of thoracic and cardiovascular surgery.

[39]  A. Björklund,et al.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  P R Sanberg,et al.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.

[41]  A. Hoffman,et al.  Chronic Treatment with Levodopa and/or Selegiline Does Not Affect Behavioral Recovery Induced by Fetal Ventral Mesencephalic Grafts in Unilaterally 6-Hydroxydopamine-Lesioned Rats , 1994, Experimental Neurology.

[42]  F. Amenta,et al.  Dopamine D5 receptors in human peripheral blood lymphocytes: A radioligand binding study , 1994, Journal of Neuroimmunology.

[43]  G. Nikkhah,et al.  Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[44]  L. Santambrogio,et al.  Dopamine receptors on human T- and B-lymphocytes , 1993, Journal of Neuroimmunology.

[45]  Y. Tanigawara,et al.  Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.

[46]  C. Marsden,et al.  The effect ofl-DOPA and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography , 1991, Neuroscience.

[47]  Richard S. J. Frackowiak,et al.  In reply: fetal brain grafts and Parkinson's disease. , 1990, Science.

[48]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[49]  P. Be´dard,et al.  Fetal dopamine neuron transplants prevent behavioral supersensitivity induced by repeated administration ofl-DOPA in the rat , 1990, Brain Research.

[50]  M. Muenter,et al.  Multi‐center study of Parkinson mortality with early versus later dopa treatment , 1987, Annals of neurology.

[51]  S. Iversen,et al.  Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions , 1981, Brain Research.

[52]  U. Ungerstedt,et al.  Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.

[53]  G. Box.  NON-NORMALITY AND TESTS ON VARIANCES , 1953 .

[54]  R. Barker,et al.  Which patients with Parkinson's disease participate in clinical trials? One centre's experiences with a new cell based therapy trial (TRANSEURO). , 2014, Journal of Parkinson's disease.

[55]  O. Lindvall,et al.  Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. , 2011, Journal of Parkinson's disease.

[56]  P. Jenner,et al.  Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-DOPA and carbidopa , 2005, Experimental Brain Research.

[57]  K. Steece-Collier,et al.  Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting , 2004, Experimental Brain Research.

[58]  C. Marsden,et al.  The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats. , 1990, Progress in brain research.

[59]  N. Quinn,et al.  Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.

[60]  S B Dunnett,et al.  Intracerebral grafting of neuronal cell suspensions. I. Introduction and general methods of preparation. , 1983, Acta physiologica Scandinavica. Supplementum.